MATN - Mateon Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2400
0.0000 (0.00%)
As of 3:36PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.2400
Open0.2550
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2400 - 0.2400
52 Week Range0.0500 - 0.3100
Volume9,127
Avg. Volume17,306
Market Cap19.704M
Beta (3Y Monthly)3.46
PE Ratio (TTM)N/A
EPS (TTM)-0.1160
Earnings DateApr 11, 2019 - Apr 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.55
Trade prices are not sourced from all markets
  • GlobeNewswire

    Mateon Enters into Merger Agreement with PointR Data to Leverage Disruptive AI Technology in Its Innovation-Driven Quest for a Cure of Cancer

    Mateon Therapeutics, Inc. (MATN) (“Mateon”) and PointR Data Inc. (PointR), a privately-held, developer of high performance cluster computer and artificial intelligence company, announced today that they have entered into a definitive agreement with respect to a merger, creating a publicly traded artificial intelligence (“AI”) driven immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. “We believe that the merger of Mateon and PointR will create a combined company that can generate shareholder value through a promising pipeline of next generation immunotherapies leveraging high performance, personalized and secure cluster computer for AI driven drug development and personalized healthcare deliveries,” said Vuong Trieu, Ph.D., Chairman and Chief Executive Officer of Mateon.

  • GlobeNewswire

    Oncotelic’s Patented Lead Anti-Cancer Drug Candidate as Well as Drug Delivery Platform for Brain Tumors on Track for Advanced Pivotal Phase 3 Clinical Testing

    AGOURA HILLS, Calif., July 30, 2019 -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of.

  • GlobeNewswire

    Internationally Recognized Top Neurosurgeon Joins the Medical Advisory Board of Oncotelic

    “I very much look forward to working with Dr. Sampson to diligently advance our clinical trial program for brain tumors with the vision of bringing a new and effective treatment option to adult and pediatric patients with recurrent or refractory high grade gliomas, including pediatric patients with diffuse intrinsic pontine glioma (DIPG) (WHO Grade IV) who are in urgent need for therapeutic innovations.” said Dr. Fatih Uckun, MD, PhD the Chief Medical Officer of Oncotelic and Mateon who is responsible for the clinical development of the drug portfolio.

  • GlobeNewswire

    Oncotelic Appoints Four Eminent Physician-Scientists Internationally Recognized for their Work in Oncology and Immunology to Newly Established Medical Advisory Board

    Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (MATN) dedicated to development of innovative treatments for cancer announced today that four internationally recognized clinical scholars have joined its Medical Advisory Board (MAB).

  • GlobeNewswire

    Mateon and Oncotelic Report on Continuing Integration of the two Businesses

    Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, announced today that it had relocated its corporate headquarters to 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301. On April 22, 2019, Mateon and Oncotelic, Inc. (Oncotelic) completed a reverse merger transaction under which Mateon issued new shares of common and preferred stock to the former Oncotelic stockholders. Following the transaction, former Oncotelic stockholders own approximately 85% of the outstanding equity of the combined company, and former Mateon stockholders own approximately 15% of the outstanding equity.

  • GlobeNewswire

    Mateon Reports First Quarter 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif., May 15, 2019 -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan.

  • GlobeNewswire

    Mateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product Pipeline

    Mateon Therapeutics, Inc. (MATN) and Oncotelic Inc. announced today that they have completed their previously announced merger. The combined company has a focused pipeline of TGF-β RNA Therapeutics for late stage cancers, including gliomas, pancreatic cancer and melanoma.

  • GlobeNewswire

    Mateon Enters into Merger Agreement with Oncotelic

    Mateon Therapeutics, Inc. (MATN) and Oncotelic Inc., a privately-held, late clinical-stage cancer immunotherapy company, announced today that they have entered into a definitive agreement with respect to a merger, creating a publicly traded immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. “We believe that the merger of Oncotelic and Mateon will create a combined company that can generate shareholder value through a promising pipeline of next generation immunotherapies targeting several significant cancer markets where there is a paucity of therapeutic options and lack of an effective immunotherapy protocol,” said Vuong Trieu, Ph.D., Co-Founder, Chairman and Chief Executive Officer of Oncotelic.

  • GlobeNewswire

    Mateon Therapeutics Reports Third Quarter 2018 Financial Results

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2018 -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan.

  • ACCESSWIRE

    Stonegate Capital Partners Initiates Coverage on Mateon Therapeutics, Inc.

    Mateon Therapeutics, Inc. (Mateon) is a clinical stage biopharmaceutical company that develops small molecule injectable drugs for the treatment of cancer patients, specifically targeting orphan indications. The Company is currently focused on advancing two programs, CA4P as an immuno-oncology agent for advanced metastatic melanoma and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and related myelodysplastic syndromes (MDS), with the ultimate goal of selling rights to a larger pharma player following additional clinical data.